Einzeltreffer — DigiBib

Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. The systemic antitumor therapy of advanced NSCLC has undergone renovations of chemotherapy, targeted therapy and immunotherapy, which results in greatly improved survival for patients with advanced NSCLC. Immune checkpoint inhibitors (ICIs), especially targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1), has changed the treatment paradigm of NSCLC. ICIs have become the standard treatment for advanced NSCLC without epidermal growth factor receptor(EGFR) mutation or anaplastic lymphomakinase(ALK) translocation in the first- or second-line setting, and for locally advanced NSCLC following concurrent radiotherapy and chemotherapy. ICIs are also promising in adjuvant/neoadjuvant therapy. More and more ICIs have been approved domestically for the treatment of NSCLC. Led by the NSCLC expert committee of Chinese Society of Clinical Oncology (CSCO), this consensus was developed and updated based on thoroughly reviewing domestic and foreign literatures, clinical trial data, systematic reviews, experts' discussion and the consensus(2019 version). This consensus will aid domestic clinicians in the treatment of NSCLC with ICIs. .

Titel:	[Chinese Experts Consensus on Immune Checkpoint Inhibitors  for Non-small Cell Lung Cancer (2020 Version)].
Autor/in / Beteiligte Person:	Zhou, C ; Wang, J ; Wang, B ; Cheng, Y ; Wang, Z ; Han, B ; Lu, Y ; Wu, G ; Zhang, L ; Song, Y ; Zhu, B ; Hu, Y ; Song, Q ; Ren, S ; He, Y ; Hu, X ; Zhang, J ; Yao, Y ; Zhao, H ; Chu, Q ; Duan, J ; Liu, J ; Qin, S
Link:	Full Text Finder (Volltext)
Zeitschrift:	Zhongguo fei ai za zhi = Chinese journal of lung cancer, Jg. 24 (2021-04-20), Heft 4, S. 217-235
Veröffentlichung:	2008- : Tianjin Shi : Zhongguo fei ai za zhi bian ji wei yuan hui ; <i>Original Publication</i>: Chendu Shi : Zhongguo fei ai za zhi bian ji wei yuan hui, 2021
Medientyp:	academicJournal
ISSN:	1999-6187 (electronic)
DOI:	10.3779/j.issn.1009-3419.2021.101.13
Schlagwort:	B7-H1 Antigen administration & dosage China Consensus Humans Immunotherapy Programmed Cell Death 1 Receptor administration & dosage Antineoplastic Agents, Immunological administration & dosage Carcinoma, Non-Small-Cell Lung drug therapy Immune Checkpoint Inhibitors administration & dosage Lung Neoplasms drug therapy
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: Chinese Publication Type: Consensus Development Conference; Journal Article Language: Chinese [Zhongguo Fei Ai Za Zhi] 2021 Apr 20; Vol. 24 (4), pp. 217-235. <i>Date of Electronic Publication: </i>2021 Apr 26. MeSH Terms: Antineoplastic Agents, Immunological / administration & dosage ; Carcinoma, Non-Small-Cell Lung / drug therapy ; Immune Checkpoint Inhibitors / administration & dosage ; Lung Neoplasms / drug therapy ; B7-H1 Antigen / administration & dosage ; China ; Consensus ; Humans ; Immunotherapy ; Programmed Cell Death 1 Receptor / administration & dosage References: Cancer Treat Rev. 2016 Mar;44:51-60. (PMID: 26874776) ; CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) ; JAMA Oncol. 2020 Jul 1;6(7):1063-1067. (PMID: 32271353) ; Clin Cancer Res. 2017 Apr 15;23(8):1920-1928. (PMID: 27827313) ; J Thorac Oncol. 2021 May;16(5):860-867. (PMID: 33476803) ; N Engl J Med. 2018 Jun 14;378(24):2288-2301. (PMID: 29863955) ; J Clin Oncol. 2018 Jul 1;36(19):1905-1912. (PMID: 29746230) ; J Clin Oncol. 2017 Dec 10;35(35):3924-3933. (PMID: 29023213) ; Lancet Oncol. 2018 Nov;19(11):1468-1479. (PMID: 30262187) ; N Engl J Med. 2017 Nov 16;377(20):1919-1929. (PMID: 28885881) ; J Thorac Oncol. 2020 Oct;15(10):1636-1646. (PMID: 32781263) ; J Clin Oncol. 2021 Sep 10;39(26):2872-2880. (PMID: 34251873) ; J Immunother Cancer. 2022 Oct;10(10):. (PMID: 36270733) ; Int J Cancer. 2021 May 1;148(9):2313-2320. (PMID: 33231285) ; J Clin Oncol. 2021 Jul 20;39(21):2327-2338. (PMID: 33513313) ; J Oncol Pract. 2018 Apr;14(4):247-249. (PMID: 29517954) ; Lancet. 2016 Apr 9;387(10027):1540-1550. (PMID: 26712084) ; N Engl J Med. 2020 Aug 13;383(7):640-649. (PMID: 32786189) ; Lancet. 2016 Apr 2;387(10026):1354-1356. (PMID: 26777918) ; Lancet Respir Med. 2020 Sep;8(9):895-904. (PMID: 32199466) ; Lancet Oncol. 2020 Oct;21(10):1353-1365. (PMID: 32919526) ; J Thorac Oncol. 2019 Jan;14(1):124-129. (PMID: 30138764) ; N Engl J Med. 2018 Nov 22;379(21):2040-2051. (PMID: 30280635) ; N Engl J Med. 2015 Jun 25;372(26):2509-20. (PMID: 26028255) ; Lung Cancer. 2019 Sep;135:188-195. (PMID: 31446994) ; JAMA Oncol. 2019 Jul 01;5(7):1049-1054. (PMID: 30730549) ; J Clin Oncol. 2015 Jun 10;33(17):1974-82. (PMID: 25605845) ; Nat Rev Clin Oncol. 2016 Aug;13(8):473-86. (PMID: 27141885) ; J Clin Oncol. 2013 Aug 10;31(23):2895-902. (PMID: 23835707) ; Lancet Respir Med. 2021 Mar;9(3):305-314. (PMID: 33347829) ; J Clin Oncol. 2018 Oct 1;36(28):2872-2878. (PMID: 30125216) ; Ann Oncol. 2016 Aug;27(8):1482-92. (PMID: 27069014) ; N Engl J Med. 2020 Oct 1;383(14):1328-1339. (PMID: 32997907) ; Eur J Cancer. 2018 Jan;88:38-47. (PMID: 29182990) ; Ann Oncol. 2012 Jun;23(6):1537-41. (PMID: 22039091) ; N Engl J Med. 2016 Nov 10;375(19):1823-1833. (PMID: 27718847) ; J Clin Oncol. 2021 Mar 1;39(7):723-733. (PMID: 33449799) ; Lancet. 2017 Jan 21;389(10066):255-265. (PMID: 27979383) ; Cancer Treat Rev. 2016 Apr;45:7-18. (PMID: 26922661) ; N Engl J Med. 2015 May 21;372(21):2018-28. (PMID: 25891174) ; Arthritis Rheumatol. 2019 Dec;71(12):2100-2111. (PMID: 31379105) ; JTO Clin Res Rep. 2021 Jul 01;2(8):100205. (PMID: 34590048) ; CA Cancer J Clin. 2021 Jan;71(1):7-33. (PMID: 33433946) ; J Clin Oncol. 2018 Mar 10;36(8):773-779. (PMID: 29355075) ; Lancet Oncol. 2020 May;21(5):655-663. (PMID: 32251621) ; N Engl J Med. 2015 Oct 22;373(17):1627-39. (PMID: 26412456) ; Ann Intern Med. 2018 Jan 16;168(2):121-130. (PMID: 29297009) ; Annu Rev Med. 2017 Jan 14;68:139-152. (PMID: 27860544) ; CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. (PMID: 26808342) ; Ann Transl Med. 2016 Jul;4(14):272. (PMID: 27563659) ; Annu Rev Immunol. 2016 May 20;34:539-73. (PMID: 26927206) ; JAMA Oncol. 2019 May 01;5(5):696-702. (PMID: 30816954) ; Clin Cancer Res. 2019 Oct 1;25(19):5743-5751. (PMID: 31040150) ; J Clin Oncol. 2012 Jun 10;30(17):2055-62. (PMID: 22547591) ; Lung Cancer. 2020 Sep;147:143-153. (PMID: 32717571) ; J Thorac Oncol. 2019 Sep;14(9):1628-1639. (PMID: 31121324) ; J Clin Oncol. 2008 Jul 20;26(21):3543-51. (PMID: 18506025) ; J Immunother Cancer. 2017 Nov 21;5(1):95. (PMID: 29162153) ; J Clin Oncol. 2020 May 10;38(14):1505-1517. (PMID: 32150489) ; Lancet Oncol. 2017 Mar;18(3):e143-e152. (PMID: 28271869) ; J Thorac Oncol. 2020 Oct;15(10):1657-1669. (PMID: 32599071) ; Lancet. 2016 Apr 30;387(10030):1837-46. (PMID: 26970723) ; JAMA Oncol. 2019 Sep 01;5(9):1332-1339. (PMID: 31154457) ; Cancer Res. 2018 Nov 15;78(22):6486-6496. (PMID: 30171052) ; Ann Oncol. 2016 Apr;27(4):559-74. (PMID: 26715621) ; Ann Oncol. 2017 Oct 01;28(10):2377-2385. (PMID: 28945858) ; N Engl J Med. 2018 May 31;378(22):2078-2092. (PMID: 29658856) ; Lancet Oncol. 2019 Jul;20(7):924-937. (PMID: 31122901) ; J Thorac Oncol. 2021 Nov;16(11):1883-1892. (PMID: 34265431) ; J Thorac Oncol. 2019 May;14(5):867-875. (PMID: 30659987) ; Immunity. 2013 Jul 25;39(1):1-10. (PMID: 23890059) ; Lung Cancer. 2017 Aug;110:26-31. (PMID: 28676214) ; J Thorac Oncol. 2020 Apr;15(4):556-567. (PMID: 31843683) ; N Engl J Med. 2015 Jul 9;373(2):123-35. (PMID: 26028407) ; N Engl J Med. 2017 Jun 22;376(25):2415-2426. (PMID: 28636851) ; Clin Cancer Res. 2015 Feb 15;21(4):687-92. (PMID: 25501578) ; JAMA Oncol. 2018 Nov 1;4(11):1543-1552. (PMID: 30193240) ; Science. 2013 Dec 20;342(6165):1417. (PMID: 24357273) ; N Engl J Med. 2013 Apr 18;368(16):1509-1518. (PMID: 23527958) ; Lancet. 2019 May 4;393(10183):1819-1830. (PMID: 30955977) ; Lung Cancer. 2020 Jul;145:181-185. (PMID: 32423643) ; Lancet Oncol. 2016 Jul;17(7):976-983. (PMID: 27267608) ; J Thorac Oncol. 2021 Oct;16(10):1718-1732. (PMID: 34048946) ; Lung Cancer. 2015 May;88(2):117-23. (PMID: 25776466) Contributed Indexing: Keywords: Expert consensus; Immunotherapy; Lung neoplasms; Programmed cell death protein 1/Programmed death-ligand 1 ; Local Abstract: [Publisher, Chinese] 【中文题目：中国非小细胞肺癌免疫检查点抑制剂治疗 专家共识（2020年版）】【中文摘要：非小细胞肺癌（non-small cell lung cancer, NSCLC）是肺癌最常见的病理类型。晚期NSCLC的系统性抗肿瘤治疗经历了化疗、靶向治疗及免疫治疗的变革，患者总体生存时间不断延长。免疫检查点抑制剂（immune checkpoint inhibitors, ICIs），尤其是程序性死亡分子-1（programmed cell death protein 1, PD-1）/程序性死亡分子配体-1（programmed death-ligand 1, PD-L1）抗体已成为表皮生长因子受体（epidermal growth factor receptor, EGFR）/间变性淋巴瘤激酶（anaplastic lymphoma kinase, ALK）阴性晚期NSCLC一线及二线的标准治疗和局部晚期NSCLC同步放化疗后标准治疗，并在辅助/新辅助治疗中显示出可喜的结果，改变了NSCLC整体治疗格局。随着越来越多的ICIs在国内获批肺癌适应证，中国临床肿瘤学会（Chinese Society of Clinical Oncology, CSCO）NSCLC专家委员会牵头，组织该领域的专家，结合2019年版专家共识，参考最新国内外文献、临床研究数据及系统评价，在专家共同讨论的基础上，达成统一意见并制定、更新本共识，为国内同行更好地应用ICIs治疗NSCLC提供参考意见。 】【中文关键词：肺肿瘤；免疫治疗；程序性死亡分子-1/程序性死亡分子配体-1；专家共识】. Substance Nomenclature: 0 (Antineoplastic Agents, Immunological) ; 0 (B7-H1 Antigen) ; 0 (Immune Checkpoint Inhibitors) ; 0 (Programmed Cell Death 1 Receptor) Entry Date(s): Date Created: 20210425 Date Completed: 20211005 Latest Revision: 20240402 Update Code: 20240402 PubMed Central ID: PMC8105610

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

[Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2020 Version)].

[Chinese Experts Consensus on Immune Checkpoint Inhibitors  for Non-small Cell Lung Cancer (2020 Version)].